Texture Analysis of Advanced Non-small Cell Lung Cancer (NSCLC) on Contrast-enhanced Computed Tomography: Prediction of the Response to the First-line Chemotherapy

Overview

Journal Eur Radiol

Specialty Radiology

Date 2013 Jul 10

PMID 23835926

Citations 66

Authors

Marco Ravanelli

Davide Farina

Mauro Morassi

Elisa Roca

Giuseppe Cavalleri

Gianfranco Tassi

Roberto Maroldi

Affiliations

Soon will be listed here.

Abstract

Objectives: To assess whether tumour heterogeneity, quantified by texture analysis (TA) on contrast-enhanced computed tomography (CECT), can predict response to chemotherapy in advanced non-small cell lung cancer (NSCLC).

Methods: Fifty-three CECT studies of patients with advanced NSCLC who had undergone first-line chemotherapy were retrospectively reviewed. Response to chemotherapy was evaluated according to RECIST1.1. Tumour uniformity was assessed by a TA method based on Laplacian of Gaussian filtering. The resulting parameters were correlated with treatment response and overall survival by multivariate analysis.

Results: Thirty-one out of 53 patients were non-responders and 22 were responders. Average overall survival was 13 months (4-35), minimum follow-up was 12 months. In the adenocarcinoma group (n = 31), the product of tumour uniformity and grey level (GL*U) was the unique independent variable correlating with treatment response. Dividing the GL*U (range 8.5-46.6) into tertiles, lesions belonging to the second and the third tertiles had an 8.3-fold higher probability of treatment response compared with those in the first tertile. No association between texture features and response to treatment was observed in the non-adenocarcinoma group (n = 22). GL*U did not correlate with overall survival.

Conclusions: TA on CECT images in advanced lung adenocarcinoma provides an independent predictive indicator of response to first-line chemotherapy.

Citing Articles

Texture analysis of CT colonography to develop a novel imaging biomarker for the management of colorectal cancer.

Mamiya H, Tochigi T, Hayano K, Ohira G, Imanishi S, Maruyama T Ann Gastroenterol Surg. 2025; 9(1):145-152.

PMID: 39759993 PMC: 11693556. DOI: 10.1002/ags3.12852.

Preoperative Prediction of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors Using a Combined CT Radiomics-Clinical Model.

Ahmed T, Zhu Z, Yasrab M, Blanco A, Kawamoto S, He J Ann Surg Oncol. 2024; 31(12):8136-8145.

PMID: 39179862 DOI: 10.1245/s10434-024-16064-4.

Advancing Cancer Treatment: Enhanced Combination Therapy through Functionalized Porous Nanoparticles.

Kim K, Park M Biomedicines. 2024; 12(2).

PMID: 38397928 PMC: 10887220. DOI: 10.3390/biomedicines12020326.

DiffusionCT: Latent Diffusion Model for CT Image Standardization.

Selim M, Zhang J, Brooks M, Wang G, Chen J AMIA Annu Symp Proc. 2024; 2023:624-633.

PMID: 38222387 PMC: 10785850.

Meta-research: How many diagnostic or prognostic models published in radiological journals are evaluated externally?.

Hameed M, Yeung J, Boone D, Mallett S, Halligan S Eur Radiol. 2023; 34(4):2524-2533.

PMID: 37696974 PMC: 10957714. DOI: 10.1007/s00330-023-10168-3.

References

Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N . Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer. 2002; 95(4):835-42. DOI: 10.1002/cncr.10730. View

Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K . Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol. 2011; 67(2):157-64. DOI: 10.1016/j.crad.2011.08.012. View

Ng F, Kozarski R, Ganeshan B, Goh V . Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis?. Eur J Radiol. 2012; 82(2):342-8. DOI: 10.1016/j.ejrad.2012.10.023. View

Song X, Liu X, Chi W, Liu Y, Wei L, Wang X . Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol. 2006; 58(6):776-84. DOI: 10.1007/s00280-006-0224-7. View

Li Y, Yang Z, Chen T, Chen H, Sun J, Lu Y . Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer. 2007; 61(1):44-53. DOI: 10.1016/j.lungcan.2007.10.021. View

Caroli P, Nanni C, Rubello D, Alavi A, Fanti S . Non-FDG PET in the practice of oncology. Indian J Cancer. 2010; 47(2):120-5. DOI: 10.4103/0019-509X.62998. View

Shanafelt T, Loprinzi C, Marks R, Novotny P, Sloan J . Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?. J Clin Oncol. 2004; 22(10):1966-74. DOI: 10.1200/JCO.2004.08.176. View

Ganeshan B, Goh V, Mandeville H, Ng Q, Hoskin P, Miles K . Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology. 2012; 266(1):326-36. DOI: 10.1148/radiol.12112428. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

10.

Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K . Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2011; 22(4):796-802. DOI: 10.1007/s00330-011-2319-8. View

11.

Gadgeel S, Cote M, Schwartz A, Matherly L, Wozniak A, Bepler G . Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat. 2010; 13(6):196-204. PMC: 3865930. DOI: 10.1016/j.drup.2010.10.001. View

12.

Mandeville H, Ng Q, Daley F, Barber P, Pierce G, Finch J . Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. Radiology. 2012; 264(2):581-9. DOI: 10.1148/radiol.12111505. View

13.

Spiro S, Rudd R, Souhami R, Brown J, Fairlamb D, Gower N . Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004; 59(10):828-36. PMC: 1746842. DOI: 10.1136/thx.2003.020164. View

14.

Padhani A . MRI for assessing antivascular cancer treatments. Br J Radiol. 2004; 76 Spec No 1:S60-80. DOI: 10.1259/bjr/15334380. View

15.

Miles K, Ganeshan B, Griffiths M, Young R, Chatwin C . Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology. 2009; 250(2):444-52. DOI: 10.1148/radiol.2502071879. View

16.

Yi C, Lee K, Kim E, Han J, Kim H, Kwon O . Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology. 2004; 233(1):191-9. DOI: 10.1148/radiol.2331031535. View